MACOP-B regimen
WikiDoc Resources for MACOP-B regimen |
Articles |
---|
Most recent articles on MACOP-B regimen Most cited articles on MACOP-B regimen |
Media |
Powerpoint slides on MACOP-B regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on MACOP-B regimen at Clinical Trials.gov Trial results on MACOP-B regimen Clinical Trials on MACOP-B regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on MACOP-B regimen NICE Guidance on MACOP-B regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on MACOP-B regimen Discussion groups on MACOP-B regimen Patient Handouts on MACOP-B regimen Directions to Hospitals Treating MACOP-B regimen Risk calculators and risk factors for MACOP-B regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for MACOP-B regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:MACOP-B Regimen; Methotrexate-Adriamycin-Cytoxan-Oncovin-Prednisone-Bleomycin Regimen
Overview
MACOP-B regimen refers to a regimen consisting of methotrexate, doxorubicin (adriamycin), cyclophosphamide, vincristine (Oncovin) and prednisone, bleomycin used to treat aggressive forms of non-Hodgkin's lymphoma.[1][2]
Regimen
MMethotrexate
ADoxorubicin (Adriamycin)
CCyclophosphamide
OVincristine (Oncovin)
PPrednisone
BBleomycin
Indications
==References==
- ↑ 1.0 1.1 De Sanctis V, Finolezzi E, Osti MF, Grapulin L, Alfò M, Pescarmona E; et al. (2008). "MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma". Int J Radiat Oncol Biol Phys. 72 (4): 1154–60. doi:10.1016/j.ijrobp.2008.02.036. PMID 18472357.
- ↑ "NCI Thesaurus".
- ↑ "NCI Thesaurus".